Sanofi Investing EUR80 Million in Germany's BioNTech
January 04 2019 - 6:52AM
Dow Jones News
By Colin Kellaher
German biotechnology company BioNTech AG on Friday said it will
receive an equity investment of 80 million euros ($91 million) from
Sanofi SA (SAN.FR, SNY) as it extends a 2015 research collaboration
with the French drug maker.
BioNTech also said it has agreed with Sanofi to co-develop the
first cancer immunotherapy candidate from the collaboration, which
is entering clinical testing in multiple solid tumors.
BioNTech, which is developing individualized immunotherapies to
treat cancer and prevent infectious diseases, in November 2015
announced the deal with Sanofi that included a $60 million upfront
payment and potential further payments topping $300 million per
product.
The Mainz, Germany, biotechnology company last year formed a
multi-year collaboration with Pfizer Inc. (PFE) to develop
messenger-RNA-based flu vaccines that included $120 million in
upfront payments and up to $305 million in potential milestone
payments.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 04, 2019 06:37 ET (11:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024